Mukka Proteins Q2 FY27 Results Await Board Approval Today
Key highlights
- Mukka Proteins is scheduled to consider Q2 FY27 and half-year results on November 7, 2026.
- Q1 FY27 net sales turnover was ₹489.65 crore, up 186.7% year on year.
- Q1 FY27 reported PAT was ₹19.59 crore, compared with ₹2.04 crore a year earlier.
- The trading window has been closed from October 1, 2026, until 48 hours after results are declared.
powered by IRIS
Mukka Proteins Limited is scheduled to consider its unaudited Q2 FY27 results on November 7, 2026, following Q1 net sales of ₹489.65 crore and reported profit after tax of ₹19.59 crore. The filing matters because it will provide the company’s first official financial update for the quarter ended September 30, 2026.
Know Mukka Proteins inside out
Results, valuation, peers and who's buying, in one view.
When will Mukka Proteins approve its Q2 FY27 results?
Mukka Proteins has informed BSE that its board is scheduled to meet on Saturday, November 7, 2026, to consider and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. As of the information provided, the Q2 figures have not been filed.
The company issued the board-meeting intimation on November 2. Its trading window has been closed from October 1, 2026, and will remain closed until 48 hours after the declaration of financial results. Such closures are a routine compliance measure intended to restrict trading by designated persons while unpublished price-sensitive information is pending.
The disclosure will cover both the July-September quarter and the first half of FY27. Investors will therefore receive the reported Q2 numbers as well as the cumulative six-month position, subject to the board’s approval and the results filed with the exchanges.
What did Mukka Proteins report in Q1 FY27?
Mukka Proteins reported net sales turnover of ₹489.65 crore for the quarter ended June 30, 2026, compared with ₹170.77 crore in the corresponding quarter a year earlier. The quarterly-results data therefore showed year-on-year sales growth of 186.7%.
Reported PAT was ₹19.59 crore in Q1 FY27, against ₹2.04 crore in Q1 FY26, according to the quarterly-results table. That represented growth of 1,072.7% on the same comparison. The same table showed total income of ₹491.25 crore, compared with ₹173.33 crore a year earlier.
The company’s regulatory financial-results extract for the June quarter separately listed revenue from operations of ₹489.65 crore, other income of ₹1.59 crore and total income of ₹491.25 crore. It listed total profit for the period at ₹18.63 crore. Readers should rely on the detailed standalone and consolidated statements filed by the company for the relevant reporting basis when comparing profit measures.
Got a follow-up? Ask IRIS
How has Mukka Proteins’ quarterly performance changed?
Mukka Proteins’ sales have varied materially across recent quarters. Sales were ₹653.50 crore in the December 2025 quarter, ₹380.60 crore in the March 2026 quarter and ₹489.65 crore in the June 2026 quarter. The June-quarter sales figure was 28.65% higher than the March-quarter figure, based on the data provided.
Profit was ₹24.42 crore in the December 2025 quarter, ₹21.23 crore in the March 2026 quarter and ₹19.59 crore in the June 2026 quarter. The Q1 FY27 PAT was 7.77% lower quarter on quarter, while remaining sharply above the low base of ₹2.04 crore reported in Q1 FY26.
The company is described as one of India’s largest manufacturers and exporters of fishmeal, fish oil and fish soluble paste. It has an estimated 25% to 30% revenue share of India’s fishmeal and fish-oil segment, according to the supplied company profile. Its quarterly results are therefore relevant to investors tracking this part of the marine-ingredients market.
What should investors assess when Q2 FY27 figures are released?
Investors can assess whether Q2 revenue sustains, exceeds or falls below the ₹489.65 crore recorded in Q1 FY27, while also comparing the result with the ₹244.58 crore sales reported for September 2025. The filing will also show whether profitability has changed from the ₹19.59 crore reported PAT in the June quarter.
Operating expenses are another relevant comparison because the supplied quarterly data shows sales and expenses moving across recent periods. The Q2 results will provide the official figures needed to evaluate revenue, expenditure, profit and any difference between standalone and consolidated performance for the half year.
No Q2 FY27 revenue, profit or margin figure should be inferred before the exchange filing. The board agenda is limited to considering and approving the unaudited results, and the final disclosed statements will be the basis for a detailed assessment of the September-quarter performance.
Conclusion
Mukka Proteins enters its Q2 FY27 board meeting after a June quarter in which net sales rose 186.7% year on year to ₹489.65 crore and reported PAT increased from ₹2.04 crore to ₹19.59 crore. The upcoming filing is important because it will establish whether the company’s first-quarter sales scale and profit level continued through the September quarter.
The next item to watch is the board-approved unaudited standalone and consolidated Q2 and half-year FY27 results scheduled for consideration on November 7, 2026. Investors can then compare the official revenue, expense and profit figures with Q1 FY27 and the September 2025 quarter.